Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.90 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.90 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.90 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.90 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.90 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL149700 | 1.00 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8374708 | 1.00 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2443249 | 0.99 | OPRD1 (0.89) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27790641 | 0.96 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27547724 | 0.95 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| US-20210370059-A1 | Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-02 | — | — | US | claimed |
| EP-3169318-B1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LTD (IE) | 2020-04-01 | — | — | EP | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| US-10238648-B2 | Abuse deterrent opioid/opioid-antagonist transdermal patch | BUZZZ PHARMACEUTICALS LTD. (IE) | 2019-03-26 | — | — | US | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| US-20170361091-A1 | Devices, Systems and Methods for Treating Urological and Gastrointestinal Disorders by Electrical Stimulation of the Foot | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-12-21 | — | — | US | claimed |
| EP-3237057-A1 | DEVICES, SYSTEMS AND METHODS FOR TREATING UROLOGICAL AND GASTROINTESTINAL DISORDERS BY ELECTRICAL STIMULATION OF THE FOOT | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| US-20170209429-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LIMITED (IE) | 2017-07-27 | — | — | US | claimed |
| EP-3169318-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | Buzzz Pharmaceuticals Limited (IE) | 2017-05-24 | — | — | EP | claimed |
| WO-2017046581-A1 | COMPOSITION COMPRISING CAV2.2 CALCIUM CHANNEL BLOCKER AND OPIOID | CALCHAN LIMITED (GB) | 2017-03-23 | — | — | WO | claimed |
| WO-2016106182-A1 | DEVICES, SYSTEMS AND METHODS FOR TREATING UROLOGICAL AND GASTROINTESTINAL DISORDERS BY ELECTRICAL STIMULATION OF THE FOOT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2016009064-A1 | ABUSE DETERRENT OPIOD/OPIOD-ANTAGONIST TRANSDERMAL PATCH | BUZZZ PHARMACEUTICALS LIMITED (IE) | 2016-01-21 | — | — | WO | claimed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20150045350-A1 | METHOD FOR NORIBOGAINE TREATMENT IN PATIENTS ON METHADONE | DEMERX, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2014143201-A1 | METHOD FOR NORIBOGAINE TREATMENT OF ADDICTION IN PATIENTS ON METHADONE | DEMERX, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013095321-A1 | HEROIN HAPTENS, IMMUNOCONJUGATES AND RELATED USES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | OPRM1 4/4885OPRD1 26/4885OPRK1 13/4885 |
| US-20150045350-A1 | METHOD FOR NORIBOGAINE TREATMENT IN PATIENTS ON METHADONE | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | OPRM1 14/4885OPRD1 12/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.